Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 5/20 | 0.35 |
| ▸ | GBA1 | P04062 | 1/20 | 0.33 |
| ▸ | CCR3 | P51677 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1000330 | 0.72 | CYP19A1 (0.61) | CYP19A1GBA1CYP11B2 | |
| SCHEMBL4932430 | 0.72 | — | — | |
| SCHEMBL1515146 | 0.70 | — | — | |
| SCHEMBL1244340 | 0.70 | — | — | |
| SCHEMBL27029414 | 0.70 | — | — | |
| SCHEMBL972354 | 0.70 | — | — | |
| SCHEMBL12470803 | 0.68 | KDM4C (0.39) | — | |
| SCHEMBL12471225 | 0.68 | GBA1 (0.33) | GBA1CCR3 | |
| SCHEMBL1481686 | 0.68 | SLC6A2 (0.37) | — | |
| SCHEMBL4824620 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140128373-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2014-05-08 | — | — | US | claimed |
| CN-103517710-A | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC | 2014-01-15 | — | — | CN | claimed |
| EP-2672967-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | Plexxikon, Inc. (US) | 2013-12-18 | — | — | EP | claimed |
| WO-2012109075-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2012-08-16 | — | — | WO | claimed |
| US-20230277534-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2023-09-07 | — | — | US | disclosed |
| US-11337976-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2022-05-24 | — | — | US | disclosed |
| EP-2672967-B1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2018-10-17 | — | — | EP | disclosed |
| US-20170157120-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2017-06-08 | — | — | US | disclosed |
| US-9624213-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-20140128373-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2014-05-08 | — | — | US | disclosed |
| CN-103517710-A | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC | 2014-01-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11337976-B2 | Compounds and methods for kinase modulation, and indications therefor | MAP3K20, PRKACA, MAP3K13 | CYP19A1 3508/4885GBA1 1318/4885CCR3 4739/4885 |
| US-20230277534-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, PRKACA, MAP3K13 | CYP19A1 3508/4885GBA1 1318/4885CCR3 4739/4885 |
| US-20140128373-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, PRKACA, MAP3K13 | CYP19A1 3508/4885GBA1 1318/4885CCR3 4739/4885 |
| US-20170157120-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, PRKACA, MAP3K13 | CYP19A1 3508/4885GBA1 1318/4885CCR3 4739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.